4D Molecular Therapeutics’ (FDMT) Sell (D-) Rating Reiterated at Weiss Ratings

4D Molecular Therapeutics (NASDAQ:FDMT)‘s stock had its “sell (d-)” rating reiterated by equities research analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Other analysts also recently issued research reports about the stock. Bank of America decreased their price target on shares of 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Leerink Partners cut their price objective on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating on the stock in a report on Monday, January 13th. Chardan Capital cut their price target on shares of 4D Molecular Therapeutics from $39.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday, February 11th. Royal Bank of Canada dropped their price objective on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a report on Thursday, November 14th. Finally, BMO Capital Markets lowered shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $40.00 to $15.00 in a report on Monday, January 13th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $32.13.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ FDMT opened at $4.72 on Wednesday. The company has a market cap of $217.97 million, a P/E ratio of -1.65 and a beta of 2.81. 4D Molecular Therapeutics has a 1 year low of $4.41 and a 1 year high of $36.25. The firm has a 50-day simple moving average of $5.46 and a two-hundred day simple moving average of $9.10.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Decheng Capital LLC raised its position in shares of 4D Molecular Therapeutics by 0.5% in the fourth quarter. Decheng Capital LLC now owns 400,000 shares of the company’s stock worth $2,228,000 after acquiring an additional 2,165 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in 4D Molecular Therapeutics by 7.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 44,324 shares of the company’s stock valued at $247,000 after acquiring an additional 2,925 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in 4D Molecular Therapeutics by 66.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock valued at $51,000 after acquiring an additional 3,630 shares in the last quarter. Rhumbline Advisers grew its stake in 4D Molecular Therapeutics by 5.3% during the 4th quarter. Rhumbline Advisers now owns 73,431 shares of the company’s stock valued at $409,000 after acquiring an additional 3,675 shares in the last quarter. Finally, ProShare Advisors LLC grew its stake in 4D Molecular Therapeutics by 30.1% during the 4th quarter. ProShare Advisors LLC now owns 16,369 shares of the company’s stock valued at $91,000 after acquiring an additional 3,783 shares in the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.